Tuesday, October 4, 2022 | Back issues
Courthouse News Service Courthouse News Service

Securities Class Action

A federal judge dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.

SAN FRANCISCO - A federal judge on Thursday dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...